These results indicate that pemetrexed-containing chemoimmunotherapy potentially improves clinical outcomes in patients with PD-L1 high-expressing non-Sq NSCLC, regardless of the TTF1 expression level, compared with non-pemetrexed chemoimmunotherapy. The gene discussed is TTF1; the disease is non-small cell lung carcinoma.